To the Editor: Dr Cushman and colleagues1 presented data from the Women’s Health Initiative
(WHI) Estrogen Plus Progestin (E + P) trial and concluded that this combination
was associated with increased risk for venous thromboembolism. The authors
note that these results apply to the combination of oral conjugated equine
estrogen (CEE) with medroxyprogesterone acetate (MPA) and are not necessarily
relevant to other types of hormone therapy; they describe the association
with transdermal estrogen therapy as controversial.
Scarabin P, Oger E, Simon T, Plu-Bureau G. Estrogen Plus Progestin and Risk of Venous Thrombosis. JAMA. 2005;293(11):1322–1323. doi:10.1001/jama.293.11.1322-a
Customize your JAMA Network experience by selecting one or more topics from the list below.